David H Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/141833/publications.pdf

Version: 2024-02-01

53 papers

3,766 citations

331670
21
h-index

43 g-index

53 all docs

53 docs citations

53 times ranked 6171 citing authors

#	Article	IF	CITATIONS
1	Factors associated with opioid-tapering success: A mixed methods study. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 248-257.e1.	1.5	8
2	Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014. Pharmacoepidemiology and Drug Safety, 2021, 30, 1541-1550.	1.9	2
3	Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensinâ€converting enzyme inhibitor therapy. Pharmacoepidemiology and Drug Safety, 2021, 30, 1630-1634.	1.9	0
4	Patient randomized trial of a targeted navigation program to improve rates of follow-up colonoscopy in community health centers. Contemporary Clinical Trials, 2020, 89, 105920.	1.8	5
5	Validity of diagnosis and procedure codes for identifying neural tube defects in infants. Pharmacoepidemiology and Drug Safety, 2020, 29, 1489-1493.	1.9	O
6	A Pharmacist-Led Program to Taper Opioid Use at Kaiser Permanente Northwest: Rationale, Design, and Evaluation. , 2020, 24, .		8
7	Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test. Population Health Management, 2019, 22, 83-89.	1.7	4
8	Identifying Preanalytic and Postanalytic Laboratory Quality Gaps Using a Data Warehouse and Structured Multidisciplinary Process. Archives of Pathology and Laboratory Medicine, 2019, 143, 518-524.	2.5	3
9	Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Internal Medicine, 2018, 178, 390.	5.1	39
10	Participatory Research to Advance Colon Cancer Prevention (PROMPT): Study protocol for a pragmatic trial. Contemporary Clinical Trials, 2018, 67, 11-15.	1.8	15
11	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 872-877.	1.9	2
12	Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. BMC Cancer, 2018, 18, 509.	2.6	15
13	A randomized, pragmatic, pharmacist-led intervention reduced opioids following orthopedic surgery. American Journal of Managed Care, 2018, 24, 515-521.	1.1	19
14	Difference in Effectiveness of Medication Adherence Intervention by Health Literacy Level. , 2016, 20, 15-200.		3
15	Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Value in Health, 2016, 19, 176-184.	0.3	18
16	Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. Trials, 2016, 17, 32.	1.6	49
17	Predicting the Risk of <i>Clostridium difficile</i> Infection upon Admission: A Score to Identify Patients for Antimicrobial Stewardship Efforts., 2016, 20, 20-25.		21
18	Study protocol for "Study of Practices Enabling Implementation and Adaptation in the Safety Net (SPREAD-NET)†a pragmatic trial comparing implementation strategies. Implementation Science, 2015, 10, 144.	6.9	9

#	Article	IF	Citations
19	Implementation challenges and successes of a population-based colorectal cancer screening program: a qualitative study of stakeholder perspectives. Implementation Science, 2015, 10, 41.	6.9	37
20	Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study. American Journal of Medicine, 2015, 128, 1252.e1-1252.e11.	1.5	7
21	Use of select dietary supplements among individuals with diabetes or atherosclerotic cardiovascular disease. Focus on Alternative and Complementary Therapies, 2014, 19, 55-63.	0.1	1
22	Guideline Concordance of Testing for Hyperkalemia and Kidney Dysfunction During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 43-50.	3.9	21
23	Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care, 2014, 20, SP502-10.	1.1	39
24	Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiology and Drug Safety, 2013, 22, 7-15.	1.9	114
25	Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 333-342.	2.2	123
26	Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA - Journal of the American Medical Association, 2012, 307, 1941-51.	7.4	810
27	Proteinuria Among Patients with Chronic Kidney Disease: A Performance Measure for Improving Patient Outcomes. Joint Commission Journal on Quality and Patient Safety, 2012, 38, 277-AP4.	0.7	5
28	Clinician's use of automated reports of estimated glomerular filtration rate: A qualitative study. BMC Nephrology, 2012, 13, 154.	1.8	6
29	Comparison of pharmacy-based measures of medication adherence. BMC Health Services Research, 2012, 12, 155.	2.2	70
30	Predicting costs of care in heart failure patients. BMC Health Services Research, 2012, 12, 434.	2.2	26
31	Medication Exposure in Pregnancy Risk Evaluation Program. Maternal and Child Health Journal, 2012, 16, 1349-1354.	1.5	57
32	Automated telephone calls to enhance colorectal cancer screening: economic analysis. American Journal of Managed Care, 2012, 18, 691-9.	1.1	17
33	Nurse-Coordinated Care in CKD: Time for Translation into Practice?. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1229-1231.	4.5	3
34	An Economic Evaluation of a Laboratory Monitoring Program for Renin-Angiotensin System Agents. Medical Decision Making, 2011, 31, 315-324.	2.4	9
35	Use of health information technology to improve medication adherence. American Journal of Managed Care, 2011, 17, SP79-87.	1.1	50
36	Automated Telephone Calls Improved Completion of Fecal Occult Blood Testing. Medical Care, 2010, 48, 604-610.	2.4	66

#	Article	IF	CITATIONS
37	Outcomes predicted by phosphorous in chronic kidney disease: a retrospective CKD-inception cohort study. Nephrology Dialysis Transplantation, 2010, 25, 166-174.	0.7	12
38	Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. Journal of Bone and Mineral Metabolism, 2009, 27, 287-294.	2.7	18
39	Reducing the Prescribing of Heavily Marketed Medications: A Randomized Controlled Trial. Journal of General Internal Medicine, 2009, 24, 897-903.	2.6	21
40	Adherence to K/DOQI Bone Metabolism Guidelines. , 2009, 19, 334-342.		2
41	Improving laboratory monitoring of medications: an economic analysis alongside a clinical trial. American Journal of Managed Care, 2009, 15, 281-9.	1.1	15
42	Lower visual acuity predicts worse utility values among patients with type 2 diabetes. Quality of Life Research, 2008, 17, 1277-1284.	3.1	35
43	A Randomized Trial of Direct-to-Patient Communication to Enhance Adherence to \hat{l}^2 -Blocker Therapy Following Myocardial Infarction. Archives of Internal Medicine, 2008, 168, 477.	3.8	65
44	Managing the Burden of Chronic Kidney Disease. Disease Management: DM, 2006, 9, 115-121.	1.0	43
45	The Impact of Prescribing Safety Alerts for Elderly Persons in an Electronic Medical Record. Archives of Internal Medicine, 2006, 166, 1098.	3.8	132
46	Improved Therapeutic Monitoring With Several Interventions. Archives of Internal Medicine, 2006, 166, 1848.	3.8	70
47	Reducing Warfarin Medication Interactions. Archives of Internal Medicine, 2006, 166, 1009.	3.8	99
48	The state of cost–effectiveness analysis in American managed care. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 229-237.	1.4	0
49	Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. Archives of Internal Medicine, 2004, 164, 659.	3.8	1,394
50	Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population. Journal of the American Society of Nephrology: JASN, 2004, 15, 1300-1306.	6.1	167
51	Pharmacovigilance in the HMO Research Network. , 0, , 391-398.		2
52	Kaiser Permanente Medical Care Program. , 0, , 241-259.		4
53	The HMO Research Network. , 0, , 261-269.		6